Comments
Loss of licensing revenue pulled biotech major Biocon's consolidated profits down 3 per cent to Rs 97.8 crore for the fourth quarter of 2011-12.
Biopharmaceuticals income from licensing income reported nil during the quarter is the main reason for lower profits.
However, the company's revenues for the quarter are up 25 per cent at Rs 611.50 crore against Rs 487.9 crore registered last year.
The company branded formulations and contract research performed well by clocking 34 per cent and 33 per cent, respectively, in the fourth quarter.
EBITDA is 6 per cent at Rs 155.90 crore and EPS stood at Rs 4.9 against Rs 5 reported in the same quarter last year.
For the whole financial year (2011-12), the company's profit dipped by eight per cent in on consolidated basis at Rs 338.40 crore against Rs 367.50 crore in the previous fiscal.
Revenues were up 16 per cent at Rs 2,148.30 crore for the year against Rs 1,857.90 crore recorded in the previous year.
EBITDA for the whole year was up one per cent at Rs 579.20 and annualised EPS was Rs 16.9 against previous year's Rs 18.4.
Ms Kiran Mazumdar-Shaw, Chairman and Managing Director, said that the company's sales have risen by 16 per cent and PAT was sustained at previous year levels despite lower net licensing income.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.